References
- Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrulli-nated peptide. Arthritis Rheum 2000;43:155–63.
- Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831–5.
- Bas S, Pemeger TV, Seitz M, Tiercy JM, Roux-Lombard P, Gueme PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheu-matology (Oxford) 2002;41:809–14.
- Meyer 0, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120–6.
- Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427 —30.
- Rantapää-Dahlqvist S, de Jong BAW, Hallmans G, Wadell G, Sundin U, van Venrooij W. Antibodies against citrulli-nated peptides (CCP) predict the development of rheumatoid arthritis. Arthritis Rheum 2002;46(Suppl):452.
- van Venrooij WJ, van de Putte LB, van den Hoogen FH. Anti-cyclic citrullinated peptide antibody in early rheumatoid arthritis: comment on the editorial by Scott. Arthritis Rheum 2003; 48:857. Author reply: 857–8.
- Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel BA, Hauselmann HJ. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 1997;36:1151–60.
- Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998;41:997— 1006.
- Lindqvist EK, Eberhardt K, Heinegard D, Saxne T. Serum-COMP for risk assessment of joint destruction in early rheumatoid arthritis. Ann Rheum Dis 2002;61(Suppl 1):81.
- den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311 — 8.
- Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583–91.
- Saxne T, Glennas A, Kvien TK, Melby K, Heinegard D. Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis. Arthritis Rheum 1993;36:20–5.
- Soderlin MK, Borjesson 0, Kautiainen H, Skogh T, Leirisalo-Repo M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002;61:911–5.
- Soderlin MK, Kautiainen H, Puolakkainen M, Hedman K, Soderlund-Venermo M, Skogh T, et al. Infections preceding early arthritis in southern Sweden: a prospective population-based study. J Rheumatol 2003;30:459–64.